Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.

ABSTRACT: Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8⁺ T cell responses, which were dependent on type 1 conventional dendritic cells, as well a

SUBMITTER: Moreo E 

PROVIDER: S-EPMC10551006 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature